Eli Lilly and United Therapeutics signed a license and supply agreement related to the U.S. commercialization rights for the pulmonary arterial hypertension (PAH) indication of Lilly's molecule, tadalafil. The PAH indication is currently under regulatory review in the U.S., Canada, Mexico, Japan, and the EU.
Under the terms of the agreements, United Therapeutics will pay $150 million to Lilly for the exclusive rights to commercialize tadalafil for PAH in the U.S., as well as for a product manufacturing and supply arrangement. Lilly will manufacture and supply tadalafil to United Therapeutics and will retain authority globally for all regulatory, development, intellectual property, and manufacturing aspects of the tadalafil molecule for all potential indications.
Additionally, Lilly will also retain commercialization rights to tadalafil for PAH outside of the U.S. and will purchase $150 million of common stock from United Therapeutics.